Skip to content

Heart EXPAND Continued Access Protocol

Heart Expand Continued Access Protocol

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03835754
Enrollment
75
Registered
2019-02-11
Start date
2019-04-17
Completion date
2022-08-12
Last updated
2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplant

Keywords

Heart preservation, Beating heart transplant

Brief summary

The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria for transplantation in this continued access protocol.

Detailed description

To provide additional data evaluating the safety and effectiveness of the OCS™ Heart System to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria (as identified above) for transplantation to potentially improve donor heart utilization for transplantation at a range of transplant centers in the U.S. and to permit patients and physicians access to the OCS Heart System while a PMA application is under preparation and review.

Interventions

The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment

Sponsors

TransMedics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(DONOR): At least one of the following: * Expected total cross-clamp time of ≥ 4 hours * Expected total cross-clamp time of ≥ 2 hours PLUS one or more of the following risk factors Donor age 45-55 years, inclusive, with no coronary catheterization data; or Donor age ≥ 55 years; or Left ventricular septal or posterior wall thickness of \>12 mm, but ≤ 16 mm; or Reported down time of ≥ 20 min, with stable hemodynamics at time of final assessment; or Left heart ejection fraction (EF) ≥ 40%, but ≤ 50% at time of acceptance of offer; or Donor angiogram with luminal irregularities with no significant CAD (≤ 50%); or History of carbon monoxide poisoning with good cardiac function at time of donor assessment; or Social history of alcoholism with good cardiac function at time of donor assessment; or History of diabetes without significant CAD (≤ 50%) on angiogram. Exclusion * CAD with \> 50% stenosis on angiogram, or * Cardiogenic shock or myocardial infarction, or * EF consistently \< 40%, or * Significant valve disease except for competent bicuspid aortic valve. Eligibility Criteria (RECIPIENT) * Registered primary heart transplant candidate * Age \>18 years old * Written informed consent. Exclusion * Prior solid organ or bone marrow transplant * Chronic use of hemodialysis or renal replacement therapy for diagnosis of chronic renal insufficiency requiring dialysis * Multi-organ transplant.

Design outcomes

Primary

MeasureTime frameDescription
Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation30 daysA composite of patient survival at Day 30 and absence of severe primary heart graft dysfunction (PGD) (LV or RV) in the first 24 hours post-transplantation according to ISHLT consensus manuscript in the protocol.

Countries

United States

Participant flow

Participants by arm

ArmCount
OCS Preservation
OCS Heart System: The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
75
Total75

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyDeath4

Baseline characteristics

CharacteristicOCS Preservation
Age, Continuous54.0 Years
STANDARD_DEVIATION 13.3
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
67 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
6 Participants
Sex: Female, Male
Female
17 Participants
Sex: Female, Male
Male
58 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
71 / 75
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
44 / 75

Outcome results

Primary

Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation

A composite of patient survival at Day 30 and absence of severe primary heart graft dysfunction (PGD) (LV or RV) in the first 24 hours post-transplantation according to ISHLT consensus manuscript in the protocol.

Time frame: 30 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
OCS PreservationPatient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation72 Participants
95% CI: [88.8, 99.2]

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026